TX, UNITED STATES, October 1, 2026 /EINPresswire.com/ -- Brown, LLC, a national whistleblower and complex litigation law firm, announced a $7.5 million settlement resolving claims under the Texas Health Care Program Fraud Prevention Act ("THFPA") in State of Texas ex rel. Tarik Ahmed v. Tris Pharma, Inc. and Ketan Mehta, Cause No. 23-1030, in the 71st Judicial District Court of Harrison County, Texas.
The State alleged that Tris Pharma promoted Dyanavel XR, an ADHD medication approved for patients age six and older, using false or misleading claims concerning the drug's efficacy and speed of onset, including a 30-minute-onset claim presented to physicians, Texas Medicaid providers, and Texas Medicaid decision-makers.
The settlement agreement expressly states that it is not an admission of facts, wrongdoing, or liability. Tris Pharma and Ketan Mehta deny liability and the allegations of wrongdoing. The settlement resolves the action in full.
This is the second Texas recovery arising from whistleblower Tarik Ahmed's efforts. In December 2025, Brown, LLC announced a $41.5 million THFPA settlement with Pfizer Inc. and Tris Pharma concerning the ADHD medication Quillivant XR, Cause No. 23-1031. Together, the two Texas matters resolved for $49 million.
Statement from Jason T. Brown, Managing Partner, Brown, LLC
“Mr. Ahmed is a real American hero. He had the courage to stand up against Big Pharma. When he saw something, he said something. His decision to come forward has now...
Hospitals will likely spend more to protect themselves from the Centers for Medicare and Medicaid Services’ expanded powers to kick them out of government health programs, which would be ruinous f...